Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 51 results for age-related macular degeneration

  1. Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment

    In development Reference number: GID-HTG10868 Expected publication date:  15 September 2026

    HealthTech guidance
    In development

  2. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  3. Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date:  11 November 2026

    Technology appraisal guidance
    Awaiting development

  4. Epiretinal brachytherapy for wet age-related macular degeneration (AMD) should only be used in the context of research. Research studies should address whether epiretinal brachytherapy reduces the progression of wet AMD and whether it can reduce the number of injections of antivascular endothelial growth factor agents (anti-VEGF) required. Long-term outcomes should be reported.

    IPG415/1 Question Epiretinal brachytherapy for wet age-related macular degeneration (AMD) should only be used in the...

    Research recommendation
    Published
    9 June 2015

  5. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820

  6. Strategies to slow the progression of age-related macular degeneration (AMD):- What is the effectiveness of antioxidant and zinc supplements on AMD disease progression for people with early AMD at high risk of progression in the context of a randomised controlled trial?

    slow the progression of age-related macular degeneration (AMD):- What is the effectiveness of antioxidant and zinc...

    Research recommendation
    Published
    13 November 2018

  7. NICE encourages further research and publication on efficacy of miniature lens system implantation for advanced age-related macular degeneration (AMD) which patients may benefit and on safety and efficacy outcomes, particularly longer-term results. NICE may update the guidance on publication of further evidence.

    efficacy of miniature lens system implantation for advanced age-related macular degeneration (AMD) which patients may...

    Research recommendation
    Published
    17 October 2016

  8. Forward view - our priority topics

    Our forward view highlights the areas we will prioritise in the coming year.

  9. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA283

  10. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development

  11. Abicipar pegol for treating wet age-related macular degeneration [ID1533]

    In development Reference number: GID-TA10511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Aflibercept for treating choroidal neovascularisation (TA486)

    Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

    Technology appraisal guidance
    Published
    1 November 2017
    View recommendations

    Sections for TA486

  13. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

    Technology appraisal guidance
    Last updated
    26 October 2023
    View recommendations

    Sections for TA274

  14. Frequency of monitoring:- What is the long-term cost effectiveness, in terms of patient-relevant outcomes including bestcorrected visual acuity and quality of life, of different review frequencies/strategies for people at risk of progression to late AMD (wet active)?

    different review frequencies/strategies for people at risk of progression to late AMD (wet active)? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    13 November 2018

  15. Self-monitoring strategies:- Does earlier detection of the incidence of late AMD (wet active) by self-monitoring in people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes?

    of the incidence of late AMD (wet active) by self-monitoring in people diagnosed with early AMD, indeterminate...

    Research recommendation
    Published
    13 November 2018